GOTHENBURG, Sweden, November 2, 2020 /PRNewswire/ — Isofol Medical AB (publ) („Isofol“), (Nasdaq First North Premier Growth Market: ISOFOL) is pleased to announce today a definitive licensing agreement with Endo Ventures Limited, a subsidiary of Endo International plc (NASDAQ: ENDP) plc, for the marketing and registration of arfolitorixine on an exclusive basis in Canada. With the agreement of Isofol, Endo Ventures Limited held Paladin Labs Inc., an Endo operating company, responsible for the application for administrative authorization for arfolitixorine in Canada and after obtaining such authorization for the marketing of arfolitixorine in Canada, including sales, marketing, medical affairs, pricing and reimbursement activities. Isofol can receive up to $US 23.05 million euros (205 million SEK) as pre-milestone, development, regulatory and sales payments. In addition, Isofol receives royalties on double-digit net sales. Isofol invites investors, analysts and media to a conference call related to the licensing agreement with Endo/Paladin. The presentation is made in English by CEO Ulf Jungnelius and ends with a question-and-answer session. Questions can be asked during the conference call or in writing via the Webcast. Pre-registration is not necessary. You agree that Paladin and its subsidiaries and representatives can collect, maintain, process and use the data you provide access to Paladin. You agree that Paladin can combine your business data, if it exists, with that of others in a way that you or someone does not personally identify.
You also give Paladin permission to share or publish summary results about search data and share or authorize it. The licensing agreement focuses on the registration and commercialization of arfolitixorine as a first-line treatment for patients with metastatic colon cancer (MCRC) in Canada. Isofol will be responsible for supplying the drug to Endo and will retain all international development rights. Isofol Medical AB (publ) is a clinical biotechnology company that develops arfolitixorine to improve the effectiveness of standard chemotherapy for advanced colon cancer by increasing tumor response and progression-free survival. Isofol has an exclusive global licensing agreement with Merck KGaA, Darmstadt, Germany, for the development and marketing of arfolitixorine for oncology indications. Isofol Medical AB (publ) is marketed on the Nasdaq First North Premier Growth Market. Certified Adviser is FNCA Sweden AB. „This licensing agreement between Isofol and Endo is a strong validation of the potential of arfolitixorine to meet unmet medical needs for patients treated with CRC.
The collaboration will enable Canadian patients to gain access to arfolitixorine after obtaining the required administrative approval, advance treatments for difficult-to-treat cancers, and promote our commitment among testimonials to promoting the quality of cancer treatment worldwide. Through Paladin, Endo has successfully commercialized innovative pharmaceuticals in Canada and our collaboration with them will be an invaluable part of our global access strategy to arfolitixorine,“ said Ulf Jungnelius, CEO of Isofol. Data is collected from third-party Paladins websites and products, including data from public public social platforms and private social platform data that Paladin has accessed, as well as user-provided information from early parties.